Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...
Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
Interesting Engineering on MSN2d
From chronic to curable: Twice-yearly shot shows near-total HIV eradicationScientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
In the PURPOSE 2 trial, lenacapavir offered almost complete protection to cisgender men, transgender women, transgender men, ...
A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...
Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
Ahead of World AIDS Day, Unitaid is announcing a US$22 million investment to accelerate the introduction and access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback